Krystal Biotech, Inc. (KRYS)
KRYS Stock Price Chart
Explore Krystal Biotech, Inc. interactive price chart. Choose custom timeframes to analyze KRYS price movements and trends.
KRYS Company Profile
Discover essential business fundamentals and corporate details for Krystal Biotech, Inc. (KRYS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Sept 2017
Employees
275.00
Website
https://www.krystalbio.comCEO
Krish S. Krishnan
Description
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
KRYS Financial Timeline
Browse a chronological timeline of Krystal Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is $1.70, while revenue estimate is $122.61m.
Earnings released on 4 May 2026
EPS came in at $1.83 surpassing the estimated $1.45 by +26.21%, while revenue for the quarter reached $116.36m , beating expectations by +3.79%.
Earnings released on 17 Feb 2026
EPS came in at $1.70 surpassing the estimated $1.62 by +4.94%, while revenue for the quarter reached $107.11m , beating expectations by +1.67%.
Earnings released on 3 Nov 2025
EPS came in at $2.66 surpassing the estimated $1.12 by +137.50%, while revenue for the quarter reached $97.80m , missing expectations by -7.12%.
Earnings released on 4 Aug 2025
EPS came in at $1.29 surpassing the estimated $1.08 by +19.44%, while revenue for the quarter reached $96.04m , beating expectations by +0.66%.
Earnings released on 6 May 2025
EPS came in at $1.20 falling short of the estimated $1.38 by -13.04%, while revenue for the quarter reached $88.18m , missing expectations by -16.79%.
Earnings released on 19 Feb 2025
EPS came in at $1.52 surpassing the estimated $1.29 by +17.83%, while revenue for the quarter reached $91.14m , missing expectations by -0.23%.
Earnings released on 4 Nov 2024
EPS came in at $0.91 surpassing the estimated $0.90 by +1.11%, while revenue for the quarter reached $83.84m , missing expectations by -8.18%.
Earnings released on 5 Aug 2024
EPS came in at $0.86 surpassing the estimated $0.50 by +72.00%, while revenue for the quarter reached $70.28m , beating expectations by +7.58%.
Earnings released on 6 May 2024
EPS came in at $0.03 falling short of the estimated $0.15 by -80.00%, while revenue for the quarter reached $45.25m , missing expectations by -4.58%.
Earnings released on 26 Feb 2024
EPS came in at $0.30 surpassing the estimated -$0.38 by +178.95%, while revenue for the quarter reached $42.14m , beating expectations by +44.52%.
Earnings released on 6 Nov 2023
EPS came in at -$0.67 surpassing the estimated -$1.10 by +39.09%, while revenue for the quarter reached $8.56m , missing expectations by -70.06%.
Earnings released on 7 Aug 2023
EPS came in at -$1.25 falling short of the estimated -$0.42 by -197.62%.
Earnings released on 8 May 2023
EPS came in at -$1.76 falling short of the estimated -$1.41 by -24.82%.
Earnings released on 27 Feb 2023
EPS came in at -$1.25 surpassing the estimated -$1.39 by +10.07%.
Earnings released on 7 Nov 2022
EPS came in at -$1.17 surpassing the estimated -$1.23 by +4.88%.
Earnings released on 8 Aug 2022
EPS came in at -$1.10 falling short of the estimated -$1.08 by -1.85%.
Earnings released on 9 May 2022
EPS came in at -$0.99 falling short of the estimated -$0.96 by -3.13%.
Earnings released on 28 Feb 2022
EPS came in at -$0.94 falling short of the estimated -$0.76 by -23.68%.
Earnings released on 8 Nov 2021
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.67%.
Earnings released on 9 Aug 2021
EPS came in at -$0.74 matching the estimated -$0.74.
KRYS Stock Performance
Access detailed KRYS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
